TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03465839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education for improving handovers quality
Description: Specific education on the importance of handovers quality will be provided. The educational session will last 4 hours. The program will be divided into the following sections: 1) a structured survey on the perception of the participants on the handovers importance; 2) Key theoretical concepts on the relevance of handovers with case studies of errors related to this critical moment; 3) showing movie clips of nursing handovers to critically interpret the clips by the participants; 4) presentation of the SBAR method recommended by WHO; 5) general presentation of the nursing delivery assessment project of the Valduce Hospital.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education for improving handovers quality
Description: Specific education on the importance of handovers quality will be provided. The educational session will last 4 hours. The program will be divided into the following sections: 1) a structured survey on the perception of the participants on the handovers importance; 2) Key theoretical concepts on the relevance of handovers with case studies of errors related to this critical moment; 3) showing movie clips of nursing handovers to critically interpret the clips by the participants; 4) presentation of the SBAR method recommended by WHO; 5) general presentation of the nursing delivery assessment project of the Valduce Hospital.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education for improving bedside handovers
Description: In addition to the education for improving handovers quality, the following intervention will be implemented for nurses assigned to the study department. The course will be supplemented by a section of the duration of an hour, containing 1) information on the principles underlying bedside handovers; 2) how to handle information in front of the patient and on his / her direct involvement; 3) role-playing of the bedside handover will be performed, assigning the roles of nurse and patient among the participants to bring out impressions linked to the functions.
Study: NCT00764777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iliac stenting
Description: Absolute Pro (Abbott Vascular) or Omnilink Elite (Abbott Vascular) stents
Study: NCT01367145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMACOR
Description: 4 capsules OMACOR 1g per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules placebo per day
Study: NCT02503527

Intervention type: OTHER
Group type: OTHER
Intervention: Diben 1.5 kcal HP
Description: Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) \> 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).

Intervention type: OTHER
Group type: OTHER
Intervention: Fresubin HP Energy Fibre (1.5 kcal)
Description: Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) \> 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
Study: NCT03201523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Socio-ecologial, community-based intervention
Description: Intervention components will include a health newsletter, health workshops, community evening/health project registration, lay leader training, neighborhood exercise groups, community walking programs with pedometers, healthy cooking contest, and school health promotion activities.
Study: NCT04414228

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: M-Entropy guidance of anesthesia depth
Description: In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the response and state entropy values between 40 and 60 from the start of anesthesia to the end of surgery. In the control group, dosage of volatile anesthetics will be titrated according to clinical judgment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProAQT in guiding goal-directed hemodynamic therapy
Description: If stroke volume variation is ≥ 10%, a bolus of 150 ml of crystalloid fluid will be given until the stroke volume variation is \< 10%. If mean arterial pressure is \< 70 mmHg and/or cardiac index \< 2.5 l·min-1·m-2 despite the stroke volume variation of \< 10% following fluid challenge, single or consecutive boluses of ephedrine 4 mg and/or continuous intravenous infusion of norepinephrine 2-10 μg·min-1 will be administered.
Study: NCT05474365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepwise training
Description: The protocol of stepwise training is mentioned in Detailed description in Study Description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepwise training
Description: The protocol of stepwise training is mentioned in Detailed description in Study Description.
Study: NCT05401734

Intervention type: DEVICE
Intervention: Observation and follow up measurement
Description: The measured variables include:~Questionnaires~* Health related quality of life (Health Related Quality of Life Questionnaire)~* Physical activity level (Physical Activity Scale for Persons with Impairments and Disabilities)~* Walking ability (Walking Index for Spinal Cord Injury)~* Independence in activities of daily living (SCIM III Questionnaire)~* Pain (International SCI Pain Basic Data Set)~* Resilience (Resilience Scale)~* Bowel and bladder function (Neurogenic Bowel Dysfunction score, International Consultation on Incontinence Modular Questionnaire - Lower Urinary Tract Symptoms)~Measurements:~* Muscular strength and joint ROM (Manual Muscle Testing)~* Spasticity (Modified Ashworth Scale)~* Walking parameters (walking time, crutch position, forward and lateral center of gravity shift, step length and height, swing phase, walking speed)~* Cardiovascular response (blood pressure, heart frequency, blood lactate concentration and Borg RPE score)

Intervention type: DEVICE
Intervention: Observation and follow up measurement
Description: The measured variables include:~Questionnaires~* Health related quality of life (Health Related Quality of Life Questionnaire)~* Physical activity level (Physical Activity Scale for Persons with Impairments and Disabilities)~* Walking ability (Walking Index for Spinal Cord Injury)~* Independence in activities of daily living (SCIM III Questionnaire)~* Pain (International SCI Pain Basic Data Set)~* Resilience (Resilience Scale)~* Bowel and bladder function (Neurogenic Bowel Dysfunction score, International Consultation on Incontinence Modular Questionnaire - Lower Urinary Tract Symptoms)~Measurements:~* Muscular strength and joint ROM (Manual Muscle Testing)~* Spasticity (Modified Ashworth Scale)~* Walking parameters (walking time, crutch position, forward and lateral center of gravity shift, step length and height, swing phase, walking speed)~* Cardiovascular response (blood pressure, heart frequency, blood lactate concentration and Borg RPE score)

Intervention type: DEVICE
Intervention: Observation and follow up measurement
Description: The measured variables include:~Questionnaires~* Health related quality of life (Health Related Quality of Life Questionnaire)~* Physical activity level (Physical Activity Scale for Persons with Impairments and Disabilities)~* Walking ability (Walking Index for Spinal Cord Injury)~* Independence in activities of daily living (SCIM III Questionnaire)~* Pain (International SCI Pain Basic Data Set)~* Resilience (Resilience Scale)~* Bowel and bladder function (Neurogenic Bowel Dysfunction score, International Consultation on Incontinence Modular Questionnaire - Lower Urinary Tract Symptoms)~Measurements:~* Muscular strength and joint ROM (Manual Muscle Testing)~* Spasticity (Modified Ashworth Scale)~* Walking parameters (walking time, crutch position, forward and lateral center of gravity shift, step length and height, swing phase, walking speed)~* Cardiovascular response (blood pressure, heart frequency, blood lactate concentration and Borg RPE score)
Study: NCT02937870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Product 1
Description: Test adhesive 1 with a thin nozzle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Product 2
Description: Test adhesive 2 with a thin nozzle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product
Description: Adhesive Cream

Intervention type: OTHER
Group type: OTHER
Intervention: Negative Control
Description: No adhesive
Study: NCT03789565

Intervention type: OTHER
Intervention: Biomarker test
Description: Diagnostic biomarker study

Intervention type: OTHER
Intervention: Biomarker test
Description: Diagnostic biomarker study

Intervention type: OTHER
Intervention: Biomarker test
Description: Diagnostic biomarker study
Study: NCT04503174

Intervention type: DEVICE
Intervention: t:slim X2 pump with Control-IQ technology
Description: Real-world use

Intervention type: DEVICE
Intervention: t:slim X2 pump with Control-IQ technology
Description: Real-world use

Intervention type: DEVICE
Intervention: t:slim X2 pump with Control-IQ technology
Description: Real-world use

Intervention type: DEVICE
Intervention: t:slim X2 pump with Control-IQ technology
Description: Real-world use

Intervention type: DEVICE
Intervention: t:slim X2 pump with Control-IQ technology
Description: Real-world use

Intervention type: DEVICE
Intervention: t:slim X2 pump with Control-IQ technology
Description: Real-world use

Intervention type: DEVICE
Intervention: t:slim X2 pump with Control-IQ technology
Description: Real-world use
Study: NCT04289870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trillium™
Description: Trillium™ Stent Graft for Functional Tricuspid Valve Replacement
Study: NCT01515592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: One daily subcutaneous dose for 5 weeks. Dose is weekly incremented with 5 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
Study: NCT03414450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1907206
Description: ETC-1907206 gelatin capsules will be dosed every other day (EOD) and contain 10 mg or 50 mg of ETC-1907206.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1907206
Description: ETC-1907206 gelatin capsules will be dosed every other day (EOD) and contain 10 mg or 50 mg of ETC-1907206.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: dasatinib tablets at 140 mg will be dosed every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: dasatinib tablets at 140 mg will be dosed every day
Study: NCT04342650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine Diphosphate
Description: 150mg tablets Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 150mg placebo tablets
Study: NCT01868945

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5 µg/day Hy.D Calcifediol
Description: 5 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 µg/day Hy.D Calcifediol
Description: 10 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15 µg/day Hy.D Calcifediol
Description: 15 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 20 µg/day vitamin D3
Description: 20 µg/day vitamin D3 taken together with breakfast for a total period of 24 weeks
Study: NCT03075761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: The Fitbit will be utilized in the intervention arm to improve adherence to a 12-week activity regimen.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 30-minute education session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 30-minute education session
Study: NCT01506076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine DiHCl
Description: Levocetirizine DiHCl Tablets 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine DiHCl
Description: Levocetirizine DiHCl Tablets 5 mg
Study: NCT04575324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Linkage Intervention
Description: Participants will be immediately linked to telemedicine care provided by an FQHC provider waivered to prescribe buprenorphine and naltrexone or able to refer patients to methadone treatment. Participants will have their vitals checked and be virtually connected to the provider. The research assistant will share the vitals with the provider, and the provider will provide personalized care during which they discuss treatment options with the participant. If a medication for opioid use disorder is prescribed or if a methadone referral is made, transportation assistance will be provided to the participant as part of the intervention. Transportation to pick up the prescription or complete the first appointment will be provided via a HIPAA compliant ride-share company, and a bus pass will be provided to the participant for the return trip.
Study: NCT00580099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assisted exercise
Description: 4 weeks of passive range of motion exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cuddle
Description: cuddle infant for 20 minutes
Study: NCT00142753

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B
Description: Standard adult dose for A1; increased adult dose for A2. Doses at Entry, Weeks 4 and 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at Week 48.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix B
Description: Standard adult dose for A1; increased adult dose for A2. Doses at Entry, Weeks 4 and 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at Week 48.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Twinrix for ATN 024
Description: Standard adult dosage, taken at Entry, Weeks 4 and 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at week 48.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombivax
Description: Dosage at entry and week 24; non-responders ((\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive 3rd dose of Recombivax during weeks 48-72.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix for ATN 025
Description: Doses at Entry and Week 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive a dose of Recombivax during week 48-72.
Study: NCT03173963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: 10 mg tablet of empagliflozin daily in addition to best clinical practice for management of diabetes.
Study: NCT04205552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML Intravenous Solution
Description: Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML Intravenous Solution
Description: Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min
Study: NCT03173963

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1placebo tablet per day
Study: NCT00818844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1%
Description: NSAID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BSS
Description: BSS
Study: NCT02584296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BSMA
Description: Biobehavioral self-management approach (BSMA) intervention is aligned with information-motivation-behavioral skills (IMB) model and is guided physical activity (PA). Collects demographic, medical, disease, treatment data, blood specimens and the battery of measures. Includes PA self-assessment, 6 minute walk test(6MWT) and chair squat test (CST) with Physical Therapist (PT); provides PA handouts based on American Cancer Society (ACS) guidelines, discusses known benefits, beliefs and goals of PA (IMB health behavior motivation); assess/discuss perceived barriers to PA. PT or Exercise physiologist (EP) works with subject on various exercises (both strength and aerobic, \~30 minutes; IMB behavioral skills);PT or EP reviews exercises, subject practices, and provides a BSMA program (including strength/aerobic training) for subject to begin upon discharge. Subject keeps journal of PA and wears accelerometer (TAA) to record PA levels. 3-weeks at home study nurse calls subjects each week.
Study: NCT00915525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A 100U or 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A 100U or 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
Study: NCT02487121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: variable interval schedule
Description: 12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-directed treatment
Description: provision of treatment materials with instruction to work through materials at participant's own pace
Study: NCT01433913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04205552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab 10 MG/ML Intravenous Solution
Description: Neoadjuvant 2 cycles, every two weeks (q2w) Relatlimab 80 mg i.v. over 30 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab 10 MG/ML Intravenous Solution
Description: Neoadjuvant 2 cycles, every two weeks (q2w) Relatlimab 80 mg i.v. over 30 min
Study: NCT01433913

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02847767

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion Imaging
Description: IV contrast perfusion CT will be performed at baseline and at 1 week after completing treatment. Perfusion imaging is similar to a diagnostic CT except a smaller region is serially imaged post contrast injection with multiple data acquisitions and high temporal resolution
Study: NCT02582632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasabuvir
Description: Tablet
Study: NCT03298061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab will be available as lyophilized powder for injection to be reconstituted with sterile water for injection, prior to use. Subjects will be dosed with mepolizumab at a dose of 300 mg which will be administered as three separate 100 mg SC injections every 4 weeks. The injections will be administered into any of the upper arm, thigh or anterior abdominal wall.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Subjects who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included.
Study: NCT00597675

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peanut OIT
Description: Defatted peanut flour ingested daily as oral mucosal immunotherapy

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oat flour matched by weight and consistency that is ingested daily as a placebo
Study: NCT01590615

Intervention type: DRUG
Intervention: Anti-HBV nucleoside/nucleotide therapy
Description: Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
Study: NCT00440024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazorac
Description: Tazarotene 0.1% cream applied to the face once daily before bed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tazorac
Description: Tazarotene 0.1% cream applied to the face once daily before bed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dove Mild Cleanser
Description: Ultra mild cleanser: Dove Non-foaming cleansing lotion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dove Mild Cleanser
Description: Ultra mild cleanser: Dove Non-foaming cleansing lotion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dove Facial Moisturizer
Description: Moisturizing cream - Dove facial moisturizer with SPF 15

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dove Facial Moisturizer
Description: Moisturizing cream - Dove facial moisturizer with SPF 15